GlassScriptPhysician profile
Paul Nassif
NPI 1154422665
$10,395.15
in general payments reported to CMS, 2019-2025
13 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 84% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,007 · 2020: $404 · 2021: $302 · 2022: $615 · 2023: $1,072 · 2024: $798 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $4,902.66 | 2019 | |
| Abbvie INC. | $2,138.48 | 2022-2025 | |
| Allergan, INC. | $1,553.68 | 2019-2022 | |
| Revance Therapeutics, INC. | $775.89 | 2024-2025 | Daxxify |
| Apyx Medical Corporation | $293.05 | 2019-2020 | |
| Galderma Laboratories, L.P. | $242.95 | 2019 | |
| Stryker Corporation | $156.79 | 2019-2023 | Scopis Ent, 1788, Xpress Ent Dilation System |
| Integra Lifesciences Corporation | $135.47 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tepha INC | $94.80 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $31.00 | 2025 | |
| Vertical Pharmaceuticals, LLC | $27.94 | 2023 | Dsuvia |
| Musculoskeletal Transplant Foundation INC. | $24.23 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $18.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Nassif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.